[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522381":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":22,"responsibleParty":35,"collaborators":7,"id":39,"slug":7,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":7,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Assiut University","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Ester A Faried, Resident","PRINCIPAL_INVESTIGATOR",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Ester A Faried, resident","CONTACT","01277194352","esterashraf1810@gmail.com",{"name":19,"role":15,"phone":20,"phoneExt":7,"email":21},"Aly M Tohamy, Professor","01006258877","Ali.Tohamy@gmail.com",[23],{"facility":5,"status":24,"city":25,"state":7,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":7},"RECRUITING","Asyut","AssiutU","Egypt","EG",{"type":30,"coordinates":31},"Point",[32,33],31.18368,27.18096,{"lat":33,"lon":32},{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Ester Ashraf Faried Beshay","Physician Resident","100522381",false,"NCT06081881","Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism","Predictors for Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism Episode","Inclusion Criteria:\n\nAny patient diagnosed as acute pulmonary embolism ,aged between 18-80 years old which Pulmonary Embolism Severity Index (PESI) class III-V or sPESI ≥1,\n\nExclusion Criteria:\n\nSecondary causes for pulmonary hypertension Severe kidney injury(eGFR\\>30 mg\u002Fdl\u002F1.7m2) Hepatic affection Contraindication to anti-coagulation","ALL","18 Years","80 Years",{"count":49,"type":50},100,"ESTIMATED","OBSERVATIONAL","to detect the incidence of CTEPH patients.\n\nPrimary outcome To predict CETHP in symptomatic patients after pulmonary embolism episode.\n\nSecondary outcome:\n\nOn Echocardiography revealed RV dysfunction which are peak TR Velocity , the RV\u002FLV basal diameter ratio, flattening of the IVS, RV acceleration time and\u002For midsystolic notching, IVC diameter with decreased inspiratory collapse and RA area.",[54],"Chronic Thromboembolic Pulmonary Hypertension",[56],"CTEPH","2025-11-27",{"date":59,"type":60},"2025-12-01","ACTUAL",{"date":62,"type":60},"2025-01-01",{"date":64,"type":50},"2026-12-01",{"name":37,"class":6},1]